Today’s EU pharmaceutical market is unsustainable, due to the fragmentation of EU players and public dependence on private interests. A recent Panel for the Future of Science and Technology (STOA) study of the EP proposes a solution involving the creation of a public European medicines infrastructure, a body that would control of the entire […]